Baidu
map

Diabetologia:经筛查有多种自身抗体的个体,其进展为1型糖尿病的风险差异较大

2020-04-12 MedSci原创 MedSci原创

患有多种自身抗体(mab)的儿童患1型糖尿病的风险非常高。我们评估了通过筛选检测到的具有单克隆抗体的人群是否也处于很高的风险中,并且该风险如何随年龄,自身抗体类型和代谢状态而变化。

患有多种自身抗体(mab)的儿童患1型糖尿病的风险非常高。我们评估了通过筛选检测到的具有单克隆抗体的人群是否也处于很高的风险中,并且该风险如何随年龄,自身抗体类型和代谢状态而变化。

研究人员分析了单抗(nal = 1815;年龄:12.35±9.39岁;范围:1-49岁)的1型糖尿病TrialNet途径。根据年龄,自身抗体类型/数量(胰岛素自身抗体[IAA],谷氨酸脱羧酶自身抗体[GADA],胰岛素瘤相关抗原2自身抗体[IA-2A]或锌转运蛋白8自身抗体[ZnT8A])评估1型糖尿病的风险Index60(空腹C肽,60分钟葡萄糖和60分钟C肽的综合量度)。 在该队列研究中使用了Cox回归和累积发生率曲线。

研究结果显示,mAbs患者的年龄与1型糖尿病风险呈负相关(HR 0.97 [95% CI 0.96, 0.99])。在2种自身抗体的参与者中,GADA患者患1型糖尿病的风险更低(HR 0.35 [95% CI 0.22, 0.57]),而IA-2A患者患1型糖尿病的风险更高(HR 2.82 [95% CI 1.76, 4.51])。IAA和GADA患者患1型糖尿病的风险只有17%。与Index60值≥1.0的患者相比,Index60 <1.0 (HR 0.23 [95% CI 0.19, 0.30])的风险明显降低。在GADA阳性、IA-2A阴性、Index60 <1.0的12%(225/1815)≥12.0岁的人群中,5年患1型糖尿病的风险为8%。

在筛查单克隆抗体的个体中,1型糖尿病的风险因年龄、自身抗体类型和代谢状态而发生显著变化。相当比例的大龄儿童和成年人携带单克隆抗体,5年后发展为1型糖尿病的风险较低。有了这些知识,预防1型糖尿病的临床试验可以更好地针对那些最有可能进展的人群。

原始出处:

Laura M. Jacobsen,Laura Bocchino,The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639435, encodeId=e067163943559, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 05 23:53:44 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761387, encodeId=1a2f1e6138759, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Oct 21 16:53:44 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043069, encodeId=dadc1043069e5, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Apr 13 00:53:44 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639435, encodeId=e067163943559, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 05 23:53:44 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761387, encodeId=1a2f1e6138759, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Oct 21 16:53:44 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043069, encodeId=dadc1043069e5, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Apr 13 00:53:44 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639435, encodeId=e067163943559, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 05 23:53:44 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761387, encodeId=1a2f1e6138759, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Oct 21 16:53:44 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043069, encodeId=dadc1043069e5, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Apr 13 00:53:44 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
    2020-04-13 misszhang

    谢谢MedSci提供最新的资讯

    0

Baidu
map
Baidu
map
Baidu
map